ARV-825
≥98%
- Product Code: 106049
CAS:
1818885-28-7
| Molecular Weight: | 923.4299999999999 g./mol | Molecular Formula: | C₄₆H₄₇ClN₈O₉S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
ARV-825 is primarily utilized in the field of cancer research, particularly in the study of targeted protein degradation. It functions as a PROTAC (Proteolysis Targeting Chimera), which is a novel approach to drug development. ARV-825 is designed to target and degrade specific proteins that are involved in cancer progression, such as BRD4. By binding to BRD4 and recruiting an E3 ubiquitin ligase, ARV-825 facilitates the ubiquitination and subsequent degradation of BRD4 via the proteasome pathway. This mechanism is particularly valuable in the treatment of cancers where BRD4 plays a critical role, such as certain types of leukemia and other hematologic malignancies. Researchers are exploring its potential to overcome resistance to traditional therapies, offering a promising avenue for the development of more effective cancer treatments.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿12,060.00 |
+
-
|
| 0.010 | 10-20 days | ฿19,287.00 |
+
-
|
ARV-825
ARV-825 is primarily utilized in the field of cancer research, particularly in the study of targeted protein degradation. It functions as a PROTAC (Proteolysis Targeting Chimera), which is a novel approach to drug development. ARV-825 is designed to target and degrade specific proteins that are involved in cancer progression, such as BRD4. By binding to BRD4 and recruiting an E3 ubiquitin ligase, ARV-825 facilitates the ubiquitination and subsequent degradation of BRD4 via the proteasome pathway. This mechanism is particularly valuable in the treatment of cancers where BRD4 plays a critical role, such as certain types of leukemia and other hematologic malignancies. Researchers are exploring its potential to overcome resistance to traditional therapies, offering a promising avenue for the development of more effective cancer treatments.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :